ArticleJournal for immunotherapy of cancer2023

SGN-B7H4V, an investigational vedotin ADC directed to the immune checkpoint ligand B7-H4, shows promising activity in preclinical models.

Elizabeth Gray et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.